Chilean President Boric Meets with SINOVAC Chairman and CEO Weidong Yin

2023-12-12

On December 12, 2023, Chilean President Gabriel Boric met with a delegation led by Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, at the Presidential Palace La Moneda in Chile. Both sides have reached a consensus on local vaccine production and collaborative research and development of health products.

President Boric firstly mentioned about his recent successful visit to China. He emphasized that during his meeting with Chinese President Xi Jinping, both leaders jointly affirmed the need to further deepen cooperation in the health care among the numerous collaborations between China and Chile. He also stated that the Chilean government has established strategic goals for the development of vaccine research and industrialization in Chile.

Yin Weidong responded, "Mr. President’s visit to China was indeed very successful. Your charisma attracted many Chinese people and won praise. The purpose of our SINOVAC delegation's special visit to Chile is to better implement the consensus reached by the top leaders of both countries. We are exploring how to accelerate collaborative projects in vaccine research and industrialization between China and Chile." Developing vaccine's research and development and localization projects in Chile is the company's long-term strategy, and SINOVAC will firmly approach this goal which is highly consistent with the strategic direction of the Chilean government.

Yin Weidong stated that both sides have set up a special working group Studying Chile's successful anti-epidemic experience during the COVID-19 epidemic. It aims to maximize Chile's research strengths in bio-pharmaceutics and leverage SINOVAC's expertise in vaccine research and localization.

The goal is to face the pandemic challenge more efficiently, to enhance vaccine's accessibility and affordability, and to contribute to the health and well-being of the people in Chile and other countries in South America.

Chilean Minister of Economy Mr. Nicolás Grau, Minister of Science Mrs. Aisén Etcheverry, Undersecretary of Public Health Mrs. Andrea Albagli, Chairman of SINOVAC Quality Committee and Head of Latin America Region Mr. Weining Meng, and Ms. Barbara Orellana, Director of Regulatory Affairs SINOVAC Chile, also presented during the meeting.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com